|
Patent landscape, scope, and claims summary: |
United States Patent 10,072,065: What Do the Claims Actually Cover and How Crowded Is the Landscape?
What is US 10,072,065 claiming, at the molecule level?
US 10,072,065 is directed to a modular peptide system that binds an immunoglobulin (via an engineered affinity ligand) and uses a blood-brain barrier (BBB) trafficking motif to ferry the immunoglobulin across the BBB, plus compositions and methods that use the peptide as a transport scaffold.
At its core, independent claim 1 recites a peptide with the general architecture:
- A_p-L_n-B_m
- A is an immunoglobulin affinity ligand comprising the sequence: H-W-R-G-W-Z (SEQ ID NO: 26)
- “Z” is a variable residue in the affinity ligand (the claim text you provided preserves “Z” but not its allowed set).
- L is a linker
- B is a BBB agent comprising a variable-position peptide motif with fixed anchors and variable residues:
- L-R-X1-R-X2-X3-X4-H-L-R-X5-X6-X7-K-R-L-X8-R-D-X9 (SEQ ID NO: 3)
- Variable constraints:
- X1: A, L, S, V
- X2: L, M
- X3: A, S
- X4: N, S, T
- X5: K, N
- X6: L, M, V
- X7: R, P
- X8: L, M
- X9: A, L
- n: 0 to 50
- m: 1 to 3
- p: 1 to 4
Claim 8 locks in one specific BBB agent sequence (SEQ ID NO: 4):
- L-R-V-R-L-A-S-H-L-R-K-L-R-K-R-L-L-R-D-A
Claim 12 locks in a specific full peptide sequence (SEQ ID NO: 42) that includes a KKKK lysine-rich segment inserted within the architecture.
Key structural implications for scope
- The immunoglobulin-binding element is narrow at the sequence level (A is exactly “H-W-R-G-W-Z”). Even with Z variability, the “handle” for non-covalent IgG capture is tightly defined relative to typical polyclonal binder systems.
- The BBB element is “constrained combinatorial” rather than a single sequence. Claim 1 allows multiple substitutions at nine positions (X1 through X9), producing a large equivalence class of BBB motifs around a conserved scaffold (fixed L, R, H, K, D and specific anchor spacing).
- The peptide length/valency is explicitly broadened by n and m.
- m (1 to 3) controls BBB motif multiplicity, which can change avidity and functional potency.
- n (0 to 50) allows extensive linker variability in length (even if L itself is defined later in dependent claims).
What is claimed beyond the peptide? (complexes and use cases)
The patent then builds a ladder of dependent claims:
-
Claims 2-3 (binding and Ig class)
- Claim 2: the affinity ligand non-covalently binds a therapeutic immunoglobulin.
- Claim 3: the therapeutic immunoglobulin is IgG.
-
Claims 4-7 (parameter and linker specifics)
- Claim 4: p = 1
- Claim 5: linker is one or more hydrophilic amino acids
- Claim 6: linker is one or more lysines
- Claim 7: n = 4
-
Claims 9-11 (immunoglobulin complexes)
- Claim 9: a complex comprising the peptide of claim 1 plus a therapeutic immunoglobulin.
- Claim 10: includes the specific BBB agent of SEQ ID NO: 4.
- Claim 11: therapeutic immunoglobulin is selected from:
cetuximab, bococizumab, dinutuximab, racotumomab, ralpancizumab, bevacizumab.
-
Claims 13-15 (transport method)
- Claim 13: method of transporting a therapeutic immunoglobulin across BBB by
- administering peptide (with the general sequence defined in claim 1) and
- concurrently administering the therapeutic immunoglobulin.
- Claim 14-15: affinity ligand non-covalently binds; immunoglobulin is IgG.
-
Claims 16-17 (treatment method)
- Claim 16: method of treating a neurological disorder using the same concurrent dosing transport scheme.
- Claim 17: neurological disorder is chosen from a list including:
- meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson’s, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer’s disease, HIV encephalitis, addiction, and cancer.
Scope mechanics that matter commercially
- The patent does not limit the IgG to a single target antigen. It captures any “therapeutic immunoglobulin” that is IgG if it is bound by the affinity ligand and used with the BBB motif peptide.
- It also captures explicit “model antibodies” in claim 11, but claim 3 already covers IgG broadly; claim 11 adds a likely litigation-friendly embodiment set.
- “Concurrently administering” narrows timing (relative dosing schedule), but does not require co-formulation, only overlap of administration windows.
How broad is the claim set in practice?
What parts are broad versus narrow?
| Claim element |
Claim language |
Practical breadth |
Litigation impact |
| Ig affinity ligand (A) |
Exact “H-W-R-G-W-Z (SEQ ID NO: 26)” |
Narrow to the defined motif |
Harder to design around by changing binder chemistry without changing the motif |
| BBB element (B) |
Fixed scaffold + variable residues X1–X9 with enumerated sets |
Broad within the defined substitution map |
High probability that many “BBB peptides” could land inside the enumerated equivalence class |
| n (linker repeats/length) |
0 to 50 |
Very broad |
Provides flexibility in manufacturing and tuning PK |
| m (BBB motif repeats) |
1 to 3 |
Broad |
Enables avidity changes; also expands infringement by capturing multiple valency formats |
| p (A repeats) |
1 to 4 |
Broad |
Allows multiple Ig-binding repeats without leaving literal scope |
| Linker identity (dependent) |
Hydrophilic; lysine in dependent claims |
Medium narrowing in dependent claims |
Mainly relevant to embodiments; base claim 1 does not require lysine linkers |
| Target IgG (dependent) |
IgG + explicit antibody list in claim 11 |
Broad (claim 3) + narrow examples (claim 11) |
Claim 11 helps with proof using commercial antibodies |
| Use (method claims) |
Neurological disorder list (claim 17) |
Broad but limited to enumerated indications |
Narrower than a full “any CNS disease” approach |
Where infringement risk concentrates
- BBB motif substitution space: Because X1–X9 are each limited to small sets, many variants could still satisfy claim 1. If a competitor uses a peptide with the same scaffold and allowable substitutions at the enumerated positions, the risk is high.
- “Concurrent” co-dosing: If a competitor injects peptide and antibody in a protocol window that a court deems concurrent, infringement risk rises even without a premade complex.
- IgG class: Many CNS programs use IgG therapeutics. If the competitor uses IgG, they fall into claim 3’s dependent framing once literal A and B are met.
What does the claim language leave ambiguous for enforcement?
How does “Z” function in the affinity ligand?
Your provided claim excerpt preserves “Z” but does not provide the allowed residue set. If Z is a variable residue with a defined set in the full patent specification, that would further expand claim 1’s reach; if Z is fixed in the patent’s definition of SEQ ID NO: 26, then the binder is even narrower than it reads.
This ambiguity matters because:
- The affinity ligand is the most sequence-constrained element in claim 1.
- If Z has multiple acceptable embodiments, a competitor may still fall within literal scope while believing they “changed” the binder.
What does “linker L” mean in claim 1?
Claim 5 narrows L to hydrophilic residues; claim 6 narrows to lysines. But claim 1 does not impose residue identity for L, only that it is a linker. That creates a broader literal scope for alternative linker chemistries unless dependent claim restrictions are relevant to a specific infringement theory.
Critical read of dependent claims: do they create new substantive coverage or just narrow embodiments?
Claim 8 and claim 10: fixed BBB sequence embodiments
- These lock in SEQ ID NO: 4 as the BBB agent.
- A competitor using this exact BBB sequence is exposed under both peptide claims and complex claims.
Claim 12: fixed full peptide sequence embodiment
- This is important because it includes a specific full sequence (SEQ ID NO: 42) with a lysine cluster (KKKK) and a specific arrangement of A, L, and B elements.
- Many CMC-driven designs use lysine-rich segments for solubility or stability. If their sequence matches or lands within the enumerated structure, they risk capture.
Claims 4 and 7: fixed parameters (p=1, n=4)
These depend on claim 1. They add fallback positions that matter if claim 1 is narrowed in claim construction:
- If a court construes A/B in ways that require more precise parameter matching, these dependent claims can preserve enforceability.
The broader patent landscape: what kinds of prior art typically collide with these claims?
A BBB-transport immunoglobulin strategy sits at the intersection of:
- IgG-binding shuttles (non-covalent antibody capture)
- BBB crossing peptides/motifs (often receptor-mediated transcytosis or BBB-penetrating peptide sequences)
- Conjugate or coadministration approaches for delivering biologics to CNS
The critical legal question is not only whether prior art discloses BBB peptides or antibody binders separately, but whether it discloses the combination and the sequence-level constraints that match the claim scaffold.
Prior art that tends to be most dangerous
- Peptide BBB shuttles with enumerated substitutions or close sequence neighbors
If the prior art uses peptides that share the same anchor residues and spacing pattern as SEQ ID NO: 3, it can map to the constrained X-position substitution scheme.
- IgG-binding ligands that are sequence-defined and non-covalent
Prior art that uses engineered affinity ligands for IgG capture increases the chance that A is not novel.
- Co-administration protocols that are “concurrent” in practice
Many studies dose transporter peptide shortly before, during, or with antibody dosing. Prior art does not have to say “concurrently” to satisfy a factual timing equivalence, depending on claim construction.
Prior art that tends to be less dangerous
- Broad BBB peptides that do not match the fixed scaffold and anchor residues.
- IgG binders that are covalent or that capture different antibody classes (not IgG).
- BBB strategies aimed at brain delivery of small molecules or non-Ig biologics.
How to interpret the claim architecture against a design-around strategy
Competitor design-around levers
- Change the affinity ligand so that it no longer matches H-W-R-G-W-Z (SEQ ID NO: 26) (binder avoidance).
- Replace the BBB motif with a different scaffold that violates one or more of the fixed-anchor residues or spacing pattern in SEQ ID NO: 3.
- Avoid “concurrent” dosing by using sequential dosing schedules that fall outside what is deemed simultaneous in enforcement.
- Use antibody formats that are not IgG (for example, Fc-silent, Fab-only, or non-Ig formats), though claim 3 specifically targets IgG.
What fails the design-around for this patent
- Using a peptide that preserves the BBB scaffold but tweaks only one of X1–X9 within allowed sets can still land in claim 1.
- Using the same binder motif with a different BBB peptide does not avoid capture if the peptide architecture still matches claim 1.
- Using lysine-rich linkers does not avoid because claim 1 already permits a wide set for L unless dependent claim restrictions are required.
Key takeaways
What the patent covers in one sentence
US 10,072,065 claims a non-covalent IgG transport system built from a defined IgG affinity ligand motif (H-W-R-G-W-Z) and a constrained variable BBB peptide scaffold (SEQ ID NO: 3), with coverage extended by repeat factors (p=1–4, n=0–50, m=1–3) and expanded into peptide-antibody complexes and concurrent co-dosing methods for enumerated neurological disorders.
High-confidence enforcement hotspots
- Any therapeutic IgG delivered with a peptide that matches the A motif and a B motif that fits the constrained X1–X9 substitution scheme.
- Embodiments that use the locked BBB sequence (SEQ ID NO: 4) and the locked full peptide sequence (SEQ ID NO: 42).
- Coadministration protocols that treat peptide and IgG as administered “concurrently.”
FAQs
1) Does US 10,072,065 require a covalent conjugate between the peptide and antibody?
No. The claims state non-covalent binding of the IgG affinity ligand to the therapeutic immunoglobulin (claims 2 and 14).
2) How many different BBB sequences are possible under claim 1’s X-position rules?
Claim 1 allows multiple combinations across X1 through X9 with limited residue sets at each position, while keeping the scaffold anchors fixed. Claim 8 and claim 10 also cover a specific BBB sequence (SEQ ID NO: 4).
3) What is the role of n, m, and p?
They define multiplicity and structural freedom:
- p (1–4) for Ig-binding affinity ligand repeats,
- n (0–50) for linker length/repetition,
- m (1–3) for BBB agent multiplicity.
4) Is the therapy limited to specific antibodies?
No. The complex claims include an explicit antibody list (claim 11), but the dependent framework already limits therapeutic immunoglobulin to IgG (claim 3). Any IgG within the claim architecture remains within scope.
5) What neurological indications are covered?
Claim 17 enumerates indications including meningitis, epilepsy, multiple sclerosis, neuromyelitis optica, late-stage neurological trypanosomiasis, Parkinson’s, progressive multifocal leukoencephalopathy, De Vivo disease, Alzheimer’s disease, HIV encephalitis, addiction, and cancer.
References
[1] United States Patent and Trademark Office. U.S. Patent 10,072,065.
More… ↓
⤷ Start Trial
|
